BACKGROUND: Whole breast irradiation reduces loco-regional recurrence and risk of death in patients submitted to breast-conserving treatment. Data show that radiation to the index quadrant alone may be enough in selected patients. AIM: To report the experience with intra-operative radiotherapy (IORT) with Electron-beam Cone in Linear Accelerator (ELIOT) and the results in overall survival, local control and late toxicity of patients submitted to this treatment. MATERIALS AND METHODS: 147 patients treated with a median follow up of 6.9 years (0.1⿿11.5 years). The actuarial local control and overall survival probabilities were estimated using the Kaplan Meier method. All tests were two-sided and p 0.05 was considered statistically significant. RESULTS: Overall survival of the cohort in 5 years, in the median follow up and in 10 years was of 98.3%, 95.1% and 95.1%, respectively, whereas local control in 5 years, in the median follow up and in 10 years was of 96%, 94.9% and 89.5%, respectively. Two risk groups were identified for local recurrence depending on the estrogen or progesterone receptors, axillary or margin status and lymphovascular invasion (LVI) (p = 0.016). CONCLUSIONS: IORT is a safe and effective treatment. Rigorous selection is important to achieve excellent local control results.
BACKGROUND: Whole breast irradiation reduces loco-regional recurrence and risk of death in patients submitted to breast-conserving treatment. Data show that radiation to the index quadrant alone may be enough in selected patients. AIM: To report the experience with intra-operative radiotherapy (IORT) with Electron-beam Cone in Linear Accelerator (ELIOT) and the results in overall survival, local control and late toxicity of patients submitted to this treatment. MATERIALS AND METHODS: 147 patients treated with a median follow up of 6.9 years (0.1⿿11.5 years). The actuarial local control and overall survival probabilities were estimated using the Kaplan Meier method. All tests were two-sided and p 0.05 was considered statistically significant. RESULTS: Overall survival of the cohort in 5 years, in the median follow up and in 10 years was of 98.3%, 95.1% and 95.1%, respectively, whereas local control in 5 years, in the median follow up and in 10 years was of 96%, 94.9% and 89.5%, respectively. Two risk groups were identified for local recurrence depending on the estrogen or progesterone receptors, axillary or margin status and lymphovascular invasion (LVI) (p = 0.016). CONCLUSIONS: IORT is a safe and effective treatment. Rigorous selection is important to achieve excellent local control results.
Authors: Maria Cristina Leonardi; Patrick Maisonneuve; Mauro Giuseppe Mastropasqua; Anna Morra; Roberta Lazzari; Nicole Rotmensz; Claudia Sangalli; Alberto Luini; Umberto Veronesi; Roberto Orecchia Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-13 Impact factor: 7.038
Authors: Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: J S Tobias; J S Vaidya; M Keshtgar; M Douek; M Metaxas; C Stacey; R Sainsbury; D D'Souza; M Baum Journal: Clin Oncol (R Coll Radiol) Date: 2006-04 Impact factor: 4.126
Authors: Donald M Cannon; Derek R McHaffie; Rakesh R Patel; Jarrod B Adkison; Rupak K Das; Bethany D Anderson; Heather M Geye; Søren M Bentzen; George M Cannon Journal: Ann Surg Oncol Date: 2013-05-25 Impact factor: 5.344
Authors: Vratislav Strnad; Oliver J Ott; Guido Hildebrandt; Daniela Kauer-Dorner; Hellen Knauerhase; Tibor Major; Jaroslaw Lyczek; Jose Luis Guinot; Jürgen Dunst; Cristina Gutierrez Miguelez; Pavel Slampa; Michael Allgäuer; Kristina Lössl; Bülent Polat; György Kovács; Arnt-René Fischedick; Thomas G Wendt; Rainer Fietkau; Marion Hindemith; Alexandra Resch; Anna Kulik; Leo Arribas; Peter Niehoff; Fernando Guedea; Annika Schlamann; Richard Pötter; Christine Gall; Martina Malzer; Wolfgang Uter; Csaba Polgár Journal: Lancet Date: 2015-10-19 Impact factor: 79.321
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321